The RyR (ryanodine receptor) mediates rapid Ca 2+ efflux from the ER (endoplasmic reticulum) and is responsible for triggering numerous Ca 2+ -activated physiological processes. The most studied RyRmediated process is excitation-contraction coupling in striated muscle, where plasma membrane excitation is transmitted to the cell interior and results in Ca 2+ efflux that triggers myocyte contraction. Recently, single-residue mutations in the cardiac RyR (RyR2) have been identified in families that exhibit CPVT (catecholaminergic polymorphic ventricular tachycardia), a condition in which physical or emotional stress can trigger severe tachyarrhythmias that can lead to sudden cardiac death. The RyR2 mutations in CPVT are clustered in the N-and C-terminal domains, as well as in a central domain. Further, a critical signalling role for dysfunctional RyR2 has also been implicated in the generation of arrhythmias in the common condition of HF (heart failure). We have prepared cardiac RyR2 plasmids with various CPVT mutations to enable expression and analysis of Ca 2+ release mediated by the wild-type and mutated RyR2. These studies suggest that the mutational locus may be important in the mechanism of Ca 2+ channel dysfunction. Understanding the causes of aberrant Ca 2+ release via RyR2 may assist in the development of effective treatments for the ventricular arrhythmias that often leads to sudden death in HF and in CPVT.
Introduction
The finely co-ordinated process of EC (excitation-contraction) coupling involves a number of precisely regulated protein components. Alteration of these proteins, or the environent that influences their function, is known to have pathological cellular consequences. Ion channel dysfunction causes malignant arrhythmia [1] , and autosomal dominant mutations in RyR2 (ryanodine receptor 2) are associated with two arrhythmogenic conditions {CPVT [catecholaminergic polymorphic VT (ventricular tachycardia)] and ARVC/D2 (arrhythmogenic right ventricular cardiomyopathy/dysplasia type 2)} that frequently lead to SCD (sudden cardiac death). These diseases typically manifest as exercise-and stressinduced ventricular arrhythmias occurring against a background of normal electrical and morphological cardiac function under resting conditions [2] [3] [4] . Currently, 64 CPVT/ ARVD2 mutations have been identified, clustering in discrete regions of the protein (see Figure 1 and Table 1 ) [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Similar mutational clustering occurs in the skeletal-muscle Ca MH (malignant hyperthermia) and CCD (central core disease) (reviewed by Treves et al. [19] ). Hence, CPVT and ARVD2 are considered to be the cardiac equivalents of MH and CCD.
RyR2 are large tetrameric channels (∼ 2 MDa) that regulate the release of stored Ca 2+ from the SR (sarcoplasmic reticulum) lumen during a vast array of Ca 2+ signalling processes, including EC coupling (for recent reviews, see [20, 21] ). The precise gating of RyR2 is achieved through modulation of the channel by various physiological effectors (e.g. Ca 2+ and Mg 2+ ), and a localized network of accessory proteins {including FKBP12. 6 [22] . The discovery of these RyR2 mutation-related arrhythmia syndromes has triggered a large upsurge of interest in elucidating the molecular mechanisms underlying mutant channel dysfunction, since this represents a pre-requisite for the design of new therapeutic strategies based on detailed structure-function analysis, but may also provide fundamental insights into the mechanisms of arrhythmogenic RyR2 dysfunction commonly occurring in HF (heart failure).
This mini-review discusses the recent discoveries and proposed mechanisms underlying aberrant Ca 2+ release via mutant RyR2, and how the structural enormity and multifaceted regulation of this channel may preclude a common mechanistic defect at the molecular level. Left-hand panel: schematic diagram to illustrate CPVT/ARVD2 mutations clustered in discrete regions of the RyR2 polypeptide; the N-terminus (residues 77-1724, mutations denoted by yellow triangles), the central domain (residues 2246-2534, blue triangles), the cytoplasmic portion of the I-domain (residues 3778-4201, green stars) and the transmembrane domains (residues 4497-4959, red circles). Mutations in the shaded boxes represent those that have been characterized previously (see Table 1 ). Right-hand panel: in instances where the substitution induced multiple changes (e.g. L433P changes both size and conformation), the one considered to cause most disruption to the protein structure was tallied (taken in the order charge > conformation > hydrophobicity > size). It should be noted that the apparent nature of each substitution type may be skewed by the different number of mutations occurring in each domain. Conformational-and charge-based substitutions predominate in the N-terminus, while more conservative-and hydrophobicity-based changes are seen in the central domain. Many of the substitutions in the cytoplasmic portion of the I-domain (residues 3610-4496) are for amino acids of a different size, suggesting that the channel architecture is particularly important in this region. Conservative changes (especially at predicted intra-membrane sites), as well as those thought to affect protein conformation, are particularly prevalent in the transmembrane domains, implying that these regions of the protein structure may be especially sensitive to alteration, and that they are essential for channel function.
Proposed mechanisms for defective RyR2 regulation in stress-induced ventricular arrhythmia
Is mutant channel dysfunction dependent on RyR2:FKBP12.6 dissociation?
Arrhythmias associated with CPVT exhibit bi-directional and/or polymorphic VT [5] . These triggered arrhythmias are thought to arise from DADs (delayed after-depolarizations), abnormal electrical events caused by increased diastolic SR Ca 2+ leak, which in turn activates inward, depolarizing currents via the Na + /Ca 2+ exchanger [23, 24] . This observation predicts that mutant RyR2 channels should exhibit a 'gain-of-function', i.e. CPVT mutations would sensitize the channel to activating stimuli, thereby triggering abnormal Ca 2+ leak during diastole. This phenomenon would probably be amplified by the catecholaminergic drive during stress or exercise, due to increased circulatory levels of noradrenaline (norepinephrine) and adrenaline (epinephrine).
Marks and co-workers [25] have proposed a controversial mechanistic basis for catecholaminergic-induced RyR2 dysfunction, via extrapolation of the maladaptive [7] hyperphosphorylation of RyR2 they proposed to occur during HF [26] . Their model suggests that catecholaminestimulated β-AR (β-adrenoceptor) activation triggers PKAmediated hyper-phosphorylation of RyR2 at Ser 2809 (Ser 2808 in human/mouse sequence), resulting in dissociation of the channel-stabilizing protein FKBP12.6 (also referred to as calstabin 2 [27] [25] . Interestingly, three other mutants (P2328S, Q4201R and V4653F) that exhibited decreased binding of FKBP12.6 [28] also showed significantly decreased Mg 2+ inhibition, leading to increased channel activity -a mechanism also thought to be involved in RyR1 dysregulation in MH/CCD [29] .
Many laboratories have challenged the claim that this model represents the causative mechanistic basis of RyR2 dysfunction in VT. Characterization of two mutations also studied in [25] (S2246L and R4497C) and an additional C-terminal mutant (N4104K) in HL-1 cardiomyocytes found that the mutation-linked Ca 2+ release abnormalities triggered by β-AR stimulation were associated with equivalent phosphorylation levels and normal interaction of mutant RyR2s with FKBP12.6 when compared with the wild-type [30] .
These results do not support selective FKBP12.6 dissociation from mutant RyR2 as the underlying cause of the augmented Ca 2+ release associated with malignant arrhythmia. Further studies have demonstrated that PKA phosphorylation of RyR2 at Ser 2808 (using site-directed, phosphorylationspecific antibodies) does not cause dissociation of FKBP12.6 in either recombinant or native systems [31] , and that wildtype and phosphomimetic S2809D RyR2 mutants exhibited equivalent FKBP12.6 binding and channel function [32] . Furthermore, Xiao et al. [33] have suggested that phosphorylation of another serine (Ser 2030 ) is the physiologically relevant marker of enhanced β-adrenergic stimulation in cardiac disease models. Moreover, the first CPVT transgenic mouse (R4496C) displayed characteristic exercise-induced, bi-directional VT [23] , which was absent from FKBP12.6-deficient mouse models [25, 34] . Thus the link between RyR2 phosphorylation at these sites and FKBP12.6 dissociation, as well as the relevance of these events to RyR2 Ca 2+ release dysfunction in cardiac disease remains unclear.
Is increased sensitivity to luminal Ca
2+ the unique determinant of mutant RyR2 pathology?
Chen and co-workers [35] have proposed an alternative explanation for CPVT mutation-linked RyR2 dysfunction. They investigated the C-terminal mutant R4496C also expressed in HEK-293 cells, and in bilayer experiments observed a higher P o than wild-type channels (especially at low [Ca 2+ ], when channels are normally closed), which manifested as spontaneous cytoplasmic Ca 2+ oscillations in these normally non-excitable cells [35] . More recently, this group observed that several CPVT mutants (see Table 1 ) exhibited sensitized luminal Ca 2+ activation and lowered the threshold for ER (endoplasmic reticulum) Ca 2+ release, thereby increasing the propensity for spontaneous Ca 2+ oscillations at normal levels of luminal Ca 2+ storage [a process they termed SOICR (store-overload-induced Ca 2+ release)] [36, 37] . Since the ten mutations characterized were distributed throughout the protein sequence, they proposed that this mechanism may explain all RyR2 mutant dysfunction in SCD. Interestingly, this model is concordant with that for the autosomal recessive form of CPVT caused by mutations in CSQ (an SR Ca 2+ -binding protein, thought to act as a luminal Ca 2+ sensor for RyR2) [38] .
RyRs are complex proteins with many domains that have been assigned discrete functionality [21] . Hence, the presence of numerous CPVT mutations throughout RyR2 reduces the probability of a single mechanism underpinning mutationlinked RyR2 dysfunction. Notably, there is appreciable heterogeneity in the degree of luminal sensitization, with those in the C-terminal and central domains showing an increased P o compared with wild-type at 300 µM free luminal Ca 2+ , whereas this increase was only evident at 1.2 mM Ca
2+
for N-terminal mutants [37] . In line with this disparity, it has also been shown that SCD-linked mutation can also perturb the sensitivity of channel activation by cytosolic Ca Is domain 'unzipping' a primary defect in mutant channel function?
Weakened interaction between key interactive RyR domains (termed domain 'unzipping') represents a plausible pathogenic mechanism for CPVT/ARVD2 as well as for MH/CCD [42] . This hypothesis has been tested in in vitro experiments using RyR2 domain peptides corresponding to the mutationlinked, central domain (residues 2460-2495), which enhanced ryanodine binding and Ca 2+ release. These effects were attributed to competitive binding of the central domain peptide to the N-terminal domain of the channel, thus disrupting ('unzipping') the intra-molecular interactions that normally stabilize the resting state. These effects were abolished by introducing a CPVT mutation (R2474S) into the central domain peptide, suggesting that this mutation disrupts the N-terminal-central domain interaction, leading to channel defects which the authors suggested could be arrhythmogenic in vivo [43] . The study by Yang et al. [40] recently corroborated this hypothesis using a permeabilized cardiomyocyte system, and demonstrated that peptide-induced 'unzipping' increased both the sensitivity of Ca 2+ -induced Ca 2+ release and Ca 2+ leak from the SR, phenomena linked to MH pathogenesis [19] .
Defective innate RyR2 regulation was also implicated in arrhythmogenesis during HF [44] . RyR2s from SR isolated from pacing-induced, failing canine hearts were found to be in an 'unzipped' conformation and associated with increased microsomal Ca 2+ leak, enhanced PKA-mediated RyR2 phosphorylation and decreased binding of FKBP12.6. This is noteworthy, since it implies that FKBP12.6 dissociation is a secondary event in channel dysregulation, occurring as a consequence of defective intra-domain interaction. In fact, the authors observed de-stabilized Ca 2+ leak even when phosphorylation and FKBP12.6 levels were unaffected, suggesting that these events may be circumstantial [44] . Moreover, and at odds with the model of Wehrens et al. [27] , the drug JTV519 (a derivative of the benzothiazepine class of voltagegated Ca 2+ channel blockers) inhibited Ca 2+ leak through channels derived from failing hearts in an FKBP12.6-independent manner [44] . Consequently, despite the potential clinical benefit of JTV519 as an anti-arrhythmic treatment for CPVT/ARVD2, the molecular basis of its channel-stabilizing actions remain to be fully explored. Transgenic mouse models of mutation-linked VT [23] may be vital in resolving these issues.
Is the mutational locus or nature of amino acid substitution critical for the mechanism of aberrant channel function in SCD?
The clustering of mutations into distinct domains of RyR2 (see Figure 1) , together with the phenotypic variability of CPVT/ARVD2, could imply that channel dysregulation is likely to stem from defects in several aspects of RyR2 regulation. One recent study has highlighted that functional heterogeneity exists between VT-linked mutations: Thomas et al. [45] showed that the L433P mutant exhibited a marked reduction in sensitivity to channel activation, in contrast with other mutations (R176Q/T2504M and N2386I) characterized in the same cell-based assay (HEK-293 Functional characterization of RyR1 mutations occurring in MH and CCD has shown that regional variation in mutations does appear to predict the resultant mechanistic defect e.g. N-terminal and central domain mutations are thought to destabilize RyR1, leading to a 'gain-of-function', whereas pore mutations are believed to disrupt the Ca 2+ permeation pathway (so-called 'EC uncoupled' mutants) [46] . Furthermore, it could be speculated that L433P exhibits a different functionality since it is the only mutation of the three to result from a conformation-based amino acid substitution (with the others being either charge-or hydrophobicity-based changes). However, it is difficult to propose a closely linked association between the mechanism of channel dysfunction and the nature of amino acid substitution, because at present only approx. 20% of known mutations have been characterized (see Table 1 ). Despite this, clear trends are emerging from the number of mutations currently identified which reveal that the nature of the amino acid change varies with its location in the RyR2 polypeptide (Figure 1) .
None of the CPVT/ARVD2 mutations discovered so far reside within the predicted channel pore (whereas there are approximately ten associated with CCD [19] ), and thus no data are available to identify whether RyR2 mutations in this region would alter channel conduction. It is plausible that mutations in this region may be lethal and therefore incompatible with long-term survival and consequently have not been clinically identified.
In support of our hypothesis that mutational locus may be a determinant of the precise mode of Ca 2+ release dysfunction during arrhythmogenesis, George et al. [47] showed that mutations localized in the I-domain (residues 3722-4610, N4104K and R4497C), a region proposed to transduce cytoplasmic events to regulate the channel pore [48] , exhibit a distinct pattern of conformational instability following channel activation, that was absent in signals obtained from a central domain (S2246L) mutation. This study provided evidence that subtle differences exist within defined modes of channel dysfunction, indicating that assigning mutationlinked abnormalities to a broad mechanistic basis (e.g. defective domain-domain interaction) may mask the subtleties revealed following comprehensive functional characterization on a mutation-by-mutation basis. Clearly, a significant challenge remains to elucidate the contributory roles of the candidate mechanisms in triggering RyR2 channel defects, compared with those that are not directly causative of channel abnormalities, but that occur as a downstream consequence of RyR2 dysfunction.
Note added in proof (received 4 September 2006)
Further mutations have been reported since submission of this paper: V186M, S3938R and T4196A [49] , and R2359Q and F4851C [50] .
